Cargando…
Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645483/ http://dx.doi.org/10.1186/2051-1426-3-S2-P126 |
| _version_ | 1782400822766731264 |
|---|---|
| author | Prithviraj, Prashanth McArthur, Grant Atkinson, Victoria Parente, Phillip Andrews, Miles Parakh, Sagun Millward, Michael Cebon, Jonathan Klein, Oliver |
| author_facet | Prithviraj, Prashanth McArthur, Grant Atkinson, Victoria Parente, Phillip Andrews, Miles Parakh, Sagun Millward, Michael Cebon, Jonathan Klein, Oliver |
| author_sort | Prithviraj, Prashanth |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4645483 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46454832015-11-20 Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy Prithviraj, Prashanth McArthur, Grant Atkinson, Victoria Parente, Phillip Andrews, Miles Parakh, Sagun Millward, Michael Cebon, Jonathan Klein, Oliver J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645483/ http://dx.doi.org/10.1186/2051-1426-3-S2-P126 Text en Copyright © 2015 Prithviraj et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Prithviraj, Prashanth McArthur, Grant Atkinson, Victoria Parente, Phillip Andrews, Miles Parakh, Sagun Millward, Michael Cebon, Jonathan Klein, Oliver Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy |
| title | Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy |
| title_full | Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy |
| title_fullStr | Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy |
| title_full_unstemmed | Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy |
| title_short | Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy |
| title_sort | updated efficacy and toxicity of treatment with the anti-ctla-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-pd-1 therapy |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645483/ http://dx.doi.org/10.1186/2051-1426-3-S2-P126 |
| work_keys_str_mv | AT prithvirajprashanth updatedefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinmetastaticmelanomapatientspreviouslytreatedwithantipd1therapy AT mcarthurgrant updatedefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinmetastaticmelanomapatientspreviouslytreatedwithantipd1therapy AT atkinsonvictoria updatedefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinmetastaticmelanomapatientspreviouslytreatedwithantipd1therapy AT parentephillip updatedefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinmetastaticmelanomapatientspreviouslytreatedwithantipd1therapy AT andrewsmiles updatedefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinmetastaticmelanomapatientspreviouslytreatedwithantipd1therapy AT parakhsagun updatedefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinmetastaticmelanomapatientspreviouslytreatedwithantipd1therapy AT millwardmichael updatedefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinmetastaticmelanomapatientspreviouslytreatedwithantipd1therapy AT cebonjonathan updatedefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinmetastaticmelanomapatientspreviouslytreatedwithantipd1therapy AT kleinoliver updatedefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinmetastaticmelanomapatientspreviouslytreatedwithantipd1therapy |